Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel thrombopoietic agents.

Biree Andemariam1, Bethan Psaila, James B Bussel

  • 1New York Presbyterian Hosp., Weill Cornell Medical Center, 525 E. 68th St., Payson 695, New York, NY 10021-4870, USA.

Hematology. American Society of Hematology. Education Program
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine·2026
Same author

In a nutshell: Pandora's Box-B-cell lymphoproliferation masking inborn errors of immunity.

British journal of haematology·2026
Same author

Thrombopoietin agents and marrow fibrosis: fact or myth.

Haematologica·2026
Same author

Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?

Vaccine·2026
Same author

Motivators and Barriers Affecting Decisions to Participate in Clinical Trials for Sickle Cell Disease: United States Findings from the Quantitative LISTEN Survey.

Journal of racial and ethnic health disparities·2026
Same author

Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.

Hemoglobin·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

New thrombopoietic growth factors offer safe and effective treatments for thrombocytopenia, a condition often linked to immune thrombocytopenic purpura (ITP) and chemotherapy. These agents show promise for managing low platelet counts in various clinical settings.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Thrombocytopenia, a low platelet count, is a key feature of immune thrombocytopenic purpura (ITP) and can arise from hepatitis C, cancer, or chemotherapy.
  • Existing treatments for thrombocytopenia are limited, necessitating the development of novel therapeutic strategies.
  • Early recombinant thrombopoietin-like agents faced challenges due to antibody development, leading to their discontinuation.

Purpose of the Study:

  • To evaluate the safety, tolerability, and efficacy of second-generation thrombopoietic agents in managing thrombocytopenia.
  • To explore the potential of these agents in patients with immune thrombocytopenic purpura (ITP) and hepatitis C-related thrombocytopenia.

Main Methods:

  • Clinical development and trials of second-generation thrombopoietic growth factors.

Related Experiment Videos

  • Assessment of safety, tolerability, and efficacy in patient populations with specific causes of thrombocytopenia.

    • Main Results:

    • Second-generation thrombopoietic agents have demonstrated significant safety, tolerability, and efficacy.
    • These agents have shown positive outcomes in patients with immune thrombocytopenic purpura (ITP) and thrombocytopenia associated with hepatitis C.
    • Previous thrombopoietin-like agents were discontinued due to adverse immune reactions.

    Conclusions:

    • Second-generation thrombopoietic agents represent a promising advancement in managing various forms of thrombocytopenia.
    • These agents are expected to improve the clinical management capabilities for hematologists dealing with low platelet counts.
    • Ongoing studies continue to support the role of thrombopoietic agents in treating thrombocytopenia.